|
14, rue de la Colombière CH-1260 Nyon, Vaud, Switzerland Tel. +41-22-363-13-10 Fax +41-22-363-13-11 |
Type: Public
On the web:
http://www.mymetics.com
Employees:
3
Mymetics likes to be on the ground floor of vaccine development. The company holds a portfolio of early-stage vaccines being developed to treat HIV, malaria, herpes, and other viruses. Its key technology uses lipid-like virosomes to carry a vaccine's active ingredients. The development-stage biotech has built its portfolio up through acquisitions, and hopes it can attract a major pharmaceutical partner once it has advanced a drug candidate through early stage clinical trials. Mymetics conducts its clinical testing in Europe and Africa. Its research and development activities take place at its facilities in Switzerland, where it also secures its funding from wealthy individuals.
Key numbers for fiscal year ending December, 2008:
Sales: $0.1M
One year growth: (86.7%)
Net income: ($9.8)M
Officers:
Chairman, President, and CEO: Jacques-François Martin
CFO, Secretary, Treasurer, and Director: Biopharmaceuticals & Biotherapeutics
Competitors:
Novartis
Progenics Pharmaceuticals
Sanofi Pasteur
